Comparison Overview

Novartis

VS

UCB

Novartis

Novartis Campus, Basel, Baselstadt, 4002, CH
Last Update: 2025-12-17
View Profile
Between 800 and 849
https://www.novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 78,879
Subsidiaries: 38
12-month incidents
0
Known data breaches
0
Attack type number
1
View Profile

UCB

Allée de la Recherche, 60, Brussels, BE
Last Update: 2025-12-18
Between 800 and 849
http://www.ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. We act with thoughtful intent to ensure our work reflects the voices of those we serve. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,309
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/novartis.jpeg
Novartis
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Novartis
100%
Compliance Rate
0/4 Standards Verified
UCB
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novartis in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for UCB in 2025.

Incident History — Novartis (X = Date, Y = Severity)

Novartis cyber incidents detection timeline including parent company and subsidiaries

Incident History — UCB (X = Date, Y = Severity)

UCB cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/novartis.jpeg
Novartis
Incidents

Date Detected: 06/2022
Type:Cyber Attack
Motivation: Financial Gain
Blog: Blog
https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
Incidents

No Incident

FAQ

Novartis company demonstrates a stronger AI Cybersecurity Score compared to UCB company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Novartis company has historically faced a number of disclosed cyber incidents, whereas UCB company has not reported any.

In the current year, UCB company and Novartis company have not reported any cyber incidents.

Neither UCB company nor Novartis company has reported experiencing a ransomware attack publicly.

Neither UCB company nor Novartis company has reported experiencing a data breach publicly.

Novartis company has reported targeted cyberattacks, while UCB company has not reported such incidents publicly.

Neither Novartis company nor UCB company has reported experiencing or disclosing vulnerabilities publicly.

Neither Novartis nor UCB holds any compliance certifications.

Neither company holds any compliance certifications.

Novartis company has more subsidiaries worldwide compared to UCB company.

Novartis company employs more people globally than UCB company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Novartis nor UCB holds SOC 2 Type 1 certification.

Neither Novartis nor UCB holds SOC 2 Type 2 certification.

Neither Novartis nor UCB holds ISO 27001 certification.

Neither Novartis nor UCB holds PCI DSS certification.

Neither Novartis nor UCB holds HIPAA certification.

Neither Novartis nor UCB holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References